COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Coronavirus Guidance for NIH Applicants and Grantees:

Dr. Zhang-Zhi Hu

Dr. Zhang-Zhi Hu

Scientific Review Officer


Division of Translational and Clinical Sciences DTCS
Oncology 2 – Translational Clinical OTC
Study Section:
Cancer Diagnostics and Treatments SBIR OTC-H (10-14)

Dr. Zhang-Zhi Hu is the Scientific Reviewer Officer for the Cancer Diagnostics and Therapeutics SBIR/STTR Special Emphasis Panel in the Oncology 2 - Translational and Clinical Integrated Review Group.

Prior to joining CSR, Dr. Hu was associate professor in the department of oncology at Georgetown University Medical Center, where his research focused on identification of cancer molecular targets and biomarkers in breast and prostate cancers using proteomics, bioinformatics, and systems biology approaches. After receiving his medical degree, Dr. Hu had further training in endocrinology in Beijing Medical University, and he continued his postdoctoral research at the NIH National Institute of Child Health and Human Development, where his research focused on the characterization of prolactin receptors and the corresponding gene, and their potential roles in breast cancers. Dr. Hu published over 58 original and review articles and book chapters and presented his work at numerous international conferences in both experimental and computational areas.